Alvotech partners with LOTTE Biologics for New York biosimilar manufacturing supply
Bitget2026/10/06 20:31Alvotech entered a long-term manufacturing partnership with LOTTE Biologics to expand US-based production and global biosimilar supply. LOTTE Biologics will make drug substance for multiple antibody biosimilars at its Syracuse, New York facility for worldwide distribution. The site provides 40,000 liters of bioreactor capacity, adding to Alvotech’s manufacturing network to support demand over the next decade. Commercial supply depends on successful technology transfer, manufacturing qualification, and required regulatory approvals. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610061630OMX_____CNEWS_EN_GNW1001276638_en) on October 06, 2026, and is solely responsible for the information contained therein.
- Alvotech entered a long-term manufacturing partnership with LOTTE Biologics to expand US-based production and global biosimilar supply.
- LOTTE Biologics will make drug substance for multiple antibody biosimilars at its Syracuse, New York facility for worldwide distribution.
- The site provides 40,000 liters of bioreactor capacity, adding to Alvotech’s manufacturing network to support demand over the next decade.
- Commercial supply depends on successful technology transfer, manufacturing qualification, and required regulatory approvals.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Crypto prices
More
